Littlepage, Laurie E <br/><br/>
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.  [electronic resource] 

 -  Cancer discovery  Jul 2012 
 - 638-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-12-0093  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibiotics, Antineoplastic--pharmacology<br/>Biomarkers, Tumor--genetics<br/>Blotting, Western<br/>Breast Neoplasms--genetics<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Disease Progression<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Gene Expression Profiling<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>MCF-7 Cells<br/>Mice<br/>NIH 3T3 Cells<br/>Neoplastic Stem Cells--metabolism<br/>Oligonucleotide Array Sequence Analysis<br/>Prognosis<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Ribonucleosides--pharmacology<br/>Survival Analysis<br/>Trans-Activators--genetics<br/>Xenograft Model Antitumor Assays